These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
505 related articles for article (PubMed ID: 35371079)
1. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W Front Immunol; 2022; 13():831101. PubMed ID: 35371079 [TBL] [Abstract][Full Text] [Related]
2. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. Liao X; Zhang D Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443 [TBL] [Abstract][Full Text] [Related]
3. Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma. Li W; You J; Xue H; Liu Y; Chen J; Zheng X; Chen L; Wu C Cancer Immunol Immunother; 2024 Aug; 73(10):207. PubMed ID: 39105870 [TBL] [Abstract][Full Text] [Related]
4. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
5. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration. Jiang Y; Chen S; Li Q; Liang J; Lin W; Li J; Liu Z; Wen M; Cao M; Hong J Front Immunol; 2021; 12():612139. PubMed ID: 33679751 [TBL] [Abstract][Full Text] [Related]
6. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro. Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response. Abulihaiti Z; Li W; Yang L; Zhang H; Du A; Tang N; Lu Y; Zeng J Mol Biol Rep; 2024 Aug; 51(1):905. PubMed ID: 39133347 [TBL] [Abstract][Full Text] [Related]
8. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells. Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158 [TBL] [Abstract][Full Text] [Related]
9. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD Front Immunol; 2022; 13():902167. PubMed ID: 36003385 [TBL] [Abstract][Full Text] [Related]
10. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Li L; Wang X; Ding Y; Hui N; Su B; Yang M Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879 [TBL] [Abstract][Full Text] [Related]
11. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma. Zuo A; Lv J; Jia W; Ba Y; Liu S; Zhang Y; Weng S; Xu H; Liu L; Wang L; Han X; Liu Z BMC Cancer; 2024 Sep; 24(1):1152. PubMed ID: 39289669 [TBL] [Abstract][Full Text] [Related]
12. Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC). Shen H; Wang Z; Ren S; Wang W; Duan L; Zhu D; Zhang C; Duan Y Int Immunopharmacol; 2020 Apr; 81():106222. PubMed ID: 32007795 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma. Cheng Q; Ji W; Lv Z; Wang W; Xu Z; Chen S; Zhang W; Shao Y; Liu J; Yang Y BMC Cancer; 2024 Jul; 24(1):868. PubMed ID: 39030507 [TBL] [Abstract][Full Text] [Related]
14. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma. Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J Biologics; 2021; 15():329-341. PubMed ID: 34413629 [TBL] [Abstract][Full Text] [Related]
15. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma. Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238 [TBL] [Abstract][Full Text] [Related]
17. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134 [TBL] [Abstract][Full Text] [Related]
18. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. Shu Y; He L; Gao M; Xiao F; Yang J; Wang S; Wei H; Zhang F; Wei H Front Immunol; 2021; 12():780509. PubMed ID: 35069551 [TBL] [Abstract][Full Text] [Related]
19. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699 [TBL] [Abstract][Full Text] [Related]
20. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma. Wang N; Zhou X; Tang F; Wang X; Zhu X Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]